The Technical Analyst
Avalon GloboCare Corp. [AVCO]
Exchange: NASDAQ Capital Market Sector: Real Estate Industry: Real Estate - Services
Avalon GloboCare Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-16.52% $0.526
/ 10 nov 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.26 mill |
| EPS: | -0.102 |
| P/E: | -5.16 |
| Earnings Date: | N/A |
| SharesOutstanding: | 10.00 mill |
| Avg Daily Volume: | 0.190 mill |
| RATING 2022-12-14 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.16 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -5.16 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.461 - 0.591 ( +/- 12.36%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
| 2021-05-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
| 2022-05-01 | Tauzin W J | Buy | 8 000 | Stock Option right to buy) |
| 2022-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
| 2022-01-01 | Tauzin W J | Buy | 4 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 99.71 |
| Last 93 transactions |
| Buy: 25 020 963 | Sell: 11 207 803 |
Forecast:
01:40 - $0.549
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.526 (-16.52% ) |
| Volume | 0.432 mill |
| Avg. Vol. | 0.190 mill |
| % of Avg. Vol | 227.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AVCO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AVCO
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Latest Press Releases
2022-05-25 09:00:00 - Press Release
Avalon Globocare To Present At The Jefferies 2022 Healthcare Conference
Freehold, n.j., may 25, 2022 (globe newswire) -- avalon globocare corp. (nasdaq: avco), a leading global developer of innovative cell-based technologies and therapeutics, announced today that david jin, m.d., ph.d., president and chief executive officer, and luisa ingargiola, chief financial officer, of avalon globocare, will be presenting at the jefferies 2022 healthcare conference which is being held on june 8–10, 2022 in new york city.
2021-10-14 09:20:00 - Press Release
Avalon Globocare Jointly Files Us And International Patent Application For Breakthrough S-layer Coated Emulsome Technology (slet) For Next-generation Drug Delivery And Cellular Immunotherapy
Freehold, n.j., oct. 14, 2021 (globe newswire) -- avalon globocare corp. (nasdaq: avco) (avalon or the company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has successfully co-developed a novel platform of s-layer coated emulsome technology (slet) for next-generation drug delivery and cellular immunotherapy, together with professor uwe sleytr and the university of natural resources and life sciences (boku) in vienna, austria.
2021-10-07 09:00:00 - Press Release
Avalon Globocare And University Of Natural Resources And Life Sciences (boku) Co-develop Innovative In-silico Technology, Enabling The Design And Synthesis Of Novel Cell Membrane Receptor Targets For Cancer And Immune-related Diseases
Freehold, n.j., oct. 07, 2021 (globe newswire) -- avalon globocare corp. (nasdaq: avco) (avalon or the company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced co-development of a novel, cell-free, in-silico system to facilitate the company's drug development efforts, together with the institute for synthetic bioarchitectures at the university of natural resources and life sciences (boku) in vienna, austria. a study of the new technology was featured in the september 2021 issue of membranes, an international, peer-reviewed journal.
2021-09-08 12:11:00 - Press Release
Avalon Globocare Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Avalon Globocare Corp. - Avco
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of hebei senlang biotechnology co. ltd. to avalon globocare corp. (“the company”) (nasdaqcm: avco). under the terms of the proposed transaction, avalon will reportedly issue 81 million shares of its common stock to acquire senlangbio. ksf is seeking to determine whether the merger and the process that led to it are adequate and fair to the company’s shareholders. if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call ksf managing partner lewis s...
2021-08-04 09:00:00 - Press Release
Upmc And Pitt Develop New Cancer Immunotherapy With Avalon Globocare
Pittsburgh, aug. 04, 2021 (globe newswire) -- a new collaboration among upmc hillman cancer center, the university of pittsburgh and new jersey-based biotechnology company avalon globocare corp. (nasdaq: avco) aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients within days instead of weeks.
Latest News
2022-12-12 09:44:01 - Proactive Investors
Avalon GloboCare to continue US-centric strategy with new proposed board composition ahead of Laboratory Services MSO acquisition
Avalon GloboCare Corp (NASDAQ:ALBT) has encouraged its shareholders to vote on a number of key proposals at its upcoming annual meeting to be held on December 29, 2022, at 11am Eastern Time. Shareholders can vote on a new proposed board composition to reflect the company's continued US focus and acquisition of Laboratory Services MSO LLC, Avalon said in a statement.
2022-11-08 10:24:58 - Proactive Investors
Avalon GloboCare to acquire majority interest in Laboratory Services MSO in 'transformative' deal worth $31M
Avalon GloboCare Corp (NASDAQ:AVCO) is set to buy a 60% stake in Laboratory Services MSO as it expands its focus on lab testing and services in what it called a 'transformative' deal worth $31 million. California-headquartered Laboratory Services has completed over 600,000 tests since inception.
2022-09-29 21:15:00 - PennyStocks
Stock Market Today: What Happened & 3 Penny Stocks To Watch Now
What happened in the stock market today and Penny stocks to watch this week. The post Stock Market Today: What Happened & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-29 10:28:58 - Proactive Investors
Avalon GloboCare gets notice of allowance from US patent office for QTY fusion platform
Avalon GloboCare Corp (NASDAQ:AVCO) has received a notice of allowance from the US Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The company's QTY code is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development, the company said.
2022-08-08 10:46:53 - Proactive Investors
Avalon GloboCare says its co-developed QTY code protein code technology featured in Chemical Reviews
Avalon GloboCare Corp (NASDAQ:AVCO) said that an article featuring its QTY protein code technology was published in Chemical Reviews, the official journal of the American Chemical Society. The publication, titled “Protein Design: From the Aspect of Water Solubility and Stability,” discusses the innovative QTY protein design code, which Avalon co-designed, as a novel platform to generate water-soluble proteins for a wide spectrum of biomedical applications.
2022-06-30 09:59:46 - Proactive Investors
Avalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancer
Avalon GloboCare Corp (NASDAQ:AVCO) announced a new study incorporating artificial intelligence (AI)-enhanced protein design technology that could accelerate development of therapeutic monoclonal antibodies to treat cancer. Developed by Avalon, the QTY code technology is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins for use in clinical applications, including drug development.
2022-05-25 09:00:00 - GlobeNewsWire
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer, of Avalon GloboCare, will be presenting at the Jefferies 2022 Healthcare Conference which is being held on June 8–10, 2022 in New York City.
2022-05-18 10:53:44 - Proactive Investors
Avalon GloboCare to team up with Lu Daopei Hematology Institute to develop companion diagnostics for CAR-T cancer treatments
Avalon GloboCare Corp (NASDAQ:AVCO) has signed a memorandum of understanding with Lu Daopei Hematology Institute (LDHI) to co-develop precision companion diagnostics for chimeric antigen receptor (CAR)-T cell therapies, the company announced. LDHI is a hematology research institute based in Beijing developing precision diagnostics based on personalized genomic, proteomic, transcriptomic and metabolomic platforms.
2022-04-27 10:29:49 - Proactive Investors
Avalon GloboCare files 16 patent applications related to cellular therapies as company moves towards clinical trials
Avalon GloboCare Corp (NASDAQ:AVCO) has revealed that is has filed 16 patent applications related to novel cellular therapies and related technologies as the company moves towards clinical trials. The company said the patents were filed with US Patent and Trademark Office, the China National Trademark Office, and under the Patent Cooperation Treaty covering 36 countries.
2022-02-14 11:57:21 - Benzinga
Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.